When was Clarendon Fund Managers founded?

Clarendon Fund Managers was founded in 2001.

Where is Clarendon Fund Managers' headquarters located?

Clarendon Fund Managers' headquarters is located in Belfast ( United Kingdom ).

How many companies has Clarendon Fund Managers invested in?

Clarendon Fund Managers has invested in 108 companies, including Axial3D & Angoka.

Which companies has Clarendon Fund Managers invested in lately?

AMPLY Discovery & Stimoxygen are the latest investments by Clarendon Fund Managers.

What sectors does Clarendon Fund Managers focus on for investments?

Top sectors in Clarendon Fund Managers' portfolio are Enterprise Applications (42 investments) and HealthTech (15 investments).

What stages of companies does Clarendon Fund Managers typically invest in?

Clarendon Fund Managers primarily invests in Seed and Series A stages.

Clarendon Fund Managers - 2025 Investor Profile, Portfolio, Team & Investment Trends - Tracxn

Q: How big is Clarendon Fund Managers' investment team?

Clarendon Fund Managers has a team of 10.

Q: How many exits has Clarendon Fund Managers been involved in?

Clarendon Fund Managers' portfolio has seen 2 IPOs and 12 acquisitions.

Clarendon Fund Managers is a venture capital firm founded in 2001. It is primarily based out of Belfast, United Kingdom. As of May 2025, Clarendon Fund Managers is an active investor, having invested in 108 companies, with 6 new investments in the last 12 months. It primarily invests in Seed round in United Kingdom based startups. Its investments are spread across a wide range of sectors from Enterprise Applications to HealthTech and High Tech. Most recently it led the $1.77M Seed round of needi along with Techstart Ventures.

Overall, Clarendon Fund Managers portfolio has seen 2 IPOs and 12 acquisitions including key companies like Diaceutics, Fusion Antibodies and Art Technology Group. A lot of funds co-invest with Clarendon Fund Managers, with names like Techstart Ventures sharing a substantial percentage of its portfolio.

Clarendon Fund Managers has team of 10 people including 2 partners.

Key Metrics

Team Members

Alan Mawson, Damien Callaghan & 8 more

Portfolio Count

Axial3D, Angoka & 106 more

Portfolio Sectors

Enterprise Applications, HealthTech & 30 more

Portfolio Locations

United Kingdom, United States & 1 more

Rounds of Entry

Seed, Series A & 2 more

Portfolio IPOs

Diaceutics & Fusion Antibodies

Portfolio Acquisitions

Reform RX, Surgery Hero & 10 more

Deals in last 12 months

AMPLY Discovery, Stimoxygen & 4 more

Clarendon Fund Managers has a portfolio of 108 companies. Their most notable investments are in VascVersa and Reform RX.Their portfolio spans across United Kingdom, United States and Ireland. They have invested in Enterprise Applications, HealthTech, High Tech and 29 other sectors, across stages such as Seed, Series A and 2 more. Here is the list of top investments by Clarendon Fund Managers:

1. Axial3D

Provider of cloud-based 3D-printed medical models and surgical guides. It takes patient-specific CT and MRI scans of orthopedic injuries, and uses 3D printing technology to manufacture custom 3D printed models, which can then be used by surgeons to plan and practice complex surgical procedures, dramatically improving patient outcomes. Its product portfolio includes models for orthopedics and traumatology, cardiology and cardiac surgeries, neuro surgeries, and pre-operative planning.

Key facts about Axial3D

Founded Year: 2014
Location: Belfast (United Kingdom)
Annual Revenue: £474K as on Sep 30, 2023
Valuation: £37.2M as on Oct 16, 2023
Stage: Series C
Total Funding till date: $44.7M
Employee Count: 49 as on Jan 31, 2022
Investors: NVIDIA, Future Fund and 35 Others
Latest Funding Round: Series C, Dec 18, 2024, $18.2M
Highlight: Editors' Pick

2. Angoka

Provider of cybersecurity risk management platforms. It provides security to protect machine-to-machine communication in smart cities, smart mobility, IoT devices, automobiles, aerospace and defence, and industrial systems. It uses cryptographic protocols for connected and autonomous vehicles.

Key facts about Angoka

Founded Year: 2019
Location: Belfast (United Kingdom)
Stage: Seed
Total Funding till date: $2.74M
Employee Count: 21 as on Jan 31, 2022
Investors: Advanced Propulsion Centre UK, Seraphim and 32 Others
Latest Funding Round: Seed, Nov 08, 2022, $2.74M
Highlight: Editors' Pick

3. Cumulus Neuroscience

AI and cloud-based brain physiology analysis tool for clinical trials. It has a cloud-based platform and device that provides a next generation integrated physiological and digital biomarker platform that has the ability to perform assesment tests, analyse results, real-time data collection, and more for drug discovery.

Key facts about Cumulus Neuroscience

Founded Year: 2015
Location: Belfast (United Kingdom)
Valuation: £9.25M as on Jul 08, 2020
Stage: Series A
Total Funding till date: $15.2M
Employee Count: 41 as on Dec 31, 2021
Investors: SV Health Investors, British Business Investments and 28 Others
Latest Funding Round: Series A, May 04, 2021, $8.32M
Highlight: Editors' Pick

4. B-Secur

Provider of patented biometric authentication solutions. It has developed and patented technology to use the human heartbeat algorithm for authentication. Its technology includes a medical-grade ECG biometric technology that reads individuals heartbeat pattern to verify the identity. Its use cases include mobile transactions, bank cards, connected cars, etc. It can be used for driver authentication and health and wellness insight.

Key facts about B-Secur

Founded Year: 2014
Location: Belfast (United Kingdom)
Valuation: $27.4M as on May 01, 2020
Stage: Series B
Total Funding till date: $18.2M
Employee Count: 70 as on Dec 31, 2022
Investors: Woodford Investment Management, Kernel Capital and 46 Others
Latest Funding Round: Series B, Nov 01, 2021, $2.97M
Highlight: Editors' Pick

5. Diaceutics

Diaceutics Group acts as an integrator in the precision medicine space. The company uses analytics, software, services and consulting to enable integration of therapies and diagnostics into the treatment pathway. The company's services include strategic consulting; digital decision tools and training; laboratory test commercialization; and branding and communication of personalized medicine solutions. The Group’s divisions include: Labceutics, Diaceutics AIS, Lceltics, and Bioceutics. It client list includes Novartis, Pfizer, Boehringer Ingelheim, MedImmune, AstraZeneca and Bristol Myers-Squibb, the Bill & Melinda Gates Foundation and many more.

Key facts about Diaceutics

Founded Year: 2005
Location: Belfast (United Kingdom)
Stage: Public
Employee Count: 133 as on Dec 31, 2021
Investors: Herald Investment Management, SVB and 4 Others
Latest Funding Round: Post IPO, Jun 11, 2020, $26.1M
Highlight: Public

Want to see the entire list?

Clarendon Fund Managers has invested in 108 companies over the last 19 years, with an average of 2 new investments annually in the last 10 years. In 2024, it made 4 investments, while as of May 2025, it has made 3 investments in this year. Its most recent first time investment was in AMPLY Discovery and most recent follow-on round was in Neurovalens.

Here are Clarendon Fund Managers' Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2025 (YTD)	3	0	3
2024	3	1	4
2023	1	0	1
2022	4	0	4
2021	2	2	4
2020	2	1	3
2019	4	0	4
2018	3	0	3
2017	1	0	1

View all investments by Clarendon Fund Managers

Get Clarendon Fund Managers' portfolio delivered to your inbox!

Clarendon Fund Managers has made 18 investments in Seed stage with an average round size of $1.52M, 9 investments in Series A stage with an average round size of $5.51M, 2 investments in Series B stage with an average round size of $15.2M and 1 investment in Unattributed stage with an average round size of $699K.

Here are Clarendon Fund Managers' investments by stage:

Note: We have considered here, only first round of investments

Stage of entry	No. of Investments
Seed	18
Series A	9
Series B	2
Unattributed	1

View all investments by Clarendon Fund Managers

Clarendon Fund Managers has a diverse portfolio, with companies operating in the Enterprise Applications, Life Sciences, HealthTech, Vertical SaaS and High Tech. Notably, it has invested in 78 Tech companies, 71 Enterprise (B2B) companies, 43 Software companies and at least 22 companies focusing on Consumer (B2C).

Here are Clarendon Fund Managers' investments by sector:

Note: We have considered here, only first round of investments

Sector	No. of Investments
Enterprise Applications	17
Life Sciences	10
HealthTech	8
Vertical SaaS	7
High Tech	6
Others	24

View all investments by Clarendon Fund Managers

Clarendon Fund Managers has made most investments in United Kingdom (28), followed by United States where it has made 2 investments.

Here are Clarendon Fund Managers' investments by geography:

Note: We have considered here, only first round of investments

Country	No. of Investments
United Kingdom	28
United States	2

View all investments by Clarendon Fund Managers

Clarendon Fund Managers has made 3 investments in 2025 so far. AMPLY Discovery and Stimoxygen are the latest among them.

Here are the most recent investments by Clarendon Fund Managers:

Date	Company	Location	Round Details	Round Amount	Co-Investors
May 01, 2025	AMPLY Discovery	United Kingdom	Seed	$1.75M	Twin Path Ventures [+3]
Mar 11, 2025	Stimoxygen	United Kingdom	Seed	$1.94M	DSW Ventures [+1]
Feb 25, 2025	RETìníZE	United Kingdom	Seed	$1.64M	Qubis [+3]
Nov 19, 2024	needi	United Kingdom	Seed	$1.77M	Techstart Ventures
Sep 18, 2024	Reform RX	United States	Seed	$5.1M	British Business Bank

Get the detailed list of all investments by Clarendon Fund Managers. Download now!

See more recent investments made by Clarendon Fund Managers

2 of Clarendon Fund Managers' portfolio companies have become public. Diaceutics got listed on the London Stock Exchange (LSE), in Mar 2019 at marketcap of $77.2M and Fusion Antibodies got listed on the London Stock Exchange (LSE) at marketcap of $36.5M.

Here are Clarendon Fund Managers' portfolio companies that went public:

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Diaceutics	Mar 21, 2019	-	-	-
Fusion Antibodies	Dec 18, 2017	-	-	-

View more details about public companies in Clarendon Fund Managers' portfolio

12 companies from Clarendon Fund Managers' portfolio have been acquired. The most recent acquisition were Reform RX in May 2025 by IFit.

Here are Clarendon Fund Managers' portfolio companies that got acquired most recently:

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Reform RX	May 20, 2025	Sep 18, 2024	Seed	$5.1M
Surgery Hero	Jan 23, 2025	Nov 15, 2022	Seed	$2.35M
Haru	Mar 14, 2023	-	-	-
Titan IC	Mar 03, 2020	Jul 07, 2015	Seed	$1.32M
BittWare	May 14, 2018	-	-	-

View all acquired companies in Clarendon Fund Managers' portfolio

Clarendon Fund Managers has a team of 10 members including 2 Partners and 3 Principals located in United Kingdom. Clarendon Fund Managers' team does not sit on the board of any company as of now.

Here is a list of all team members in Clarendon Fund Managers:

Name	Designation	Location	Board Memberships	Contact details
Alan Mawson	Partner	London	-	-
Damien Callaghan	Partner	Belfast	-	1 Email
Neil Simms	Principal	Belfast	-	1 Email
Jim Curran	Principal	Belfast	-	1 Email
Brian Cummings	Principal	Belfast	-	1 Email
Stuart Gaffikin	Associate	Belfast	-	1 Email
Chris Trotter	Associate	Belfast	-	1 Email
Claudine Owens	Associate	Belfast	-	-
Sian McLaughlin	Associate	United Kingdom	-	1 Email
Peter Hutchinson	Associate	Belfast	-	1 Email

Get the full list of Clarendon Fund Managers' team & partners for free. Download now!

View team details of Clarendon Fund Managers

Over the past 19 years, 178 investors have co-invested in Clarendon Fund Managers's portfolio companies.

Invested before Clarendon Fund Managers: Techstart Ventures, Invest Northern Ireland and 63 others have invested in rounds before Clarendon Fund Managers. There are 6 companies where Techstart Ventures has invested before Clarendon Fund Managers and 4 companies where Invest Northern Ireland has invested before Clarendon Fund Managers.
Top Co-investors of Clarendon Fund Managers: 82 investors entered a company along with Clarendon Fund Managers. These include investors like Techstart Ventures (7 companies).
Invested after Clarendon Fund Managers: A total of 31 investors have invested in Clarendon Fund Managers's portfolio after their investments. Top Investors include Co-Fund NI (3 companies), British Business Bank (3 companies) and Future Fund (2 companies).